Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $21.3 Million - $23.3 Million
52,300 New
52,300 $21.9 Million
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $9.65 Million - $11 Million
34,073 Added 111.83%
64,541 $20.3 Million
Q4 2022

Feb 13, 2023

BUY
$285.76 - $321.48 $8.71 Million - $9.79 Million
30,468 New
30,468 $8.8 Million
Q3 2022

Nov 10, 2022

SELL
$273.83 - $305.53 $1.03 Million - $1.15 Million
-3,751 Closed
0 $0
Q2 2022

Aug 19, 2022

BUY
$234.96 - $292.55 $881,334 - $1.1 Million
3,751 New
3,751 $1.06 Million
Q1 2022

May 13, 2022

SELL
$221.42 - $260.97 $9.95 Million - $11.7 Million
-44,933 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $1.03 Million - $1.3 Million
5,821 Added 14.88%
44,933 $9.87 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $2.44 Million - $2.73 Million
13,450 Added 52.41%
39,112 $7.1 Million
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $3.01 Million - $3.55 Million
16,065 Added 167.4%
25,662 $5.17 Million
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $1.93 Million - $2.25 Million
-9,316 Reduced 49.26%
9,597 $2.06 Million
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $2.5 Million - $3.34 Million
12,091 Added 177.24%
18,913 $4.47 Million
Q3 2020

Nov 16, 2020

SELL
$255.65 - $303.1 $1.99 Million - $2.36 Million
-7,786 Reduced 53.3%
6,822 $1.86 Million
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $2.79 Million - $3.66 Million
12,370 Added 552.73%
14,608 $4.24 Million
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $447,085 - $554,598
2,238 New
2,238 $533,000
Q4 2019

Feb 14, 2020

SELL
$166.71 - $223.91 $1.46 Million - $1.97 Million
-8,776 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $325,145 - $365,948
1,956 Added 28.68%
8,776 $1.49 Million
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $1.12 Million - $1.3 Million
6,820 New
6,820 $1.25 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.